RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME

被引:97
作者
SPEER, CP
GEFELLER, O
GRONECK, P
LAUFKOTTER, E
ROLL, C
HANSSLER, L
HARMS, K
HERTING, E
BOENISCH, H
WINDELER, J
ROBERTSON, B
机构
[1] UNIV GOTTINGEN, DEPT PAEDIAT, GOTTINGEN, GERMANY
[2] STADT KRANKENHAUS COLOGNE, DEPT MED STAT, COLOGNE, GERMANY
[3] STADT KRANKENHAUS COLOGNE, DEPT PAEDIAT, COLOGNE, GERMANY
[4] RUHR UNIV BOCHUM, DEPT PAEDIAT, BOCHUM, GERMANY
[5] UNIV ESSEN GESAMTHSCH, DEPT PAEDIAT, ESSEN, GERMANY
[6] STADT KRANKENHAUS BRAUNSCHWEIG, BRAUNSCHWEIG, GERMANY
[7] RUHR UNIV BOCHUM, DEPT MED INFORMAT & BIOMATH, BOCHUM, GERMANY
[8] KAROLINSKA INST, KAROLINSKA HOSP, RES UNIT EXPTL PERINATAL PATHOL, S-10401 STOCKHOLM, SWEDEN
来源
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | 1995年 / 72卷 / 01期
关键词
SURFACTANT TREATMENT; RESPIRATORY DISTRESS SYNDROME; CUROSURF; SURVANTA;
D O I
10.1136/fn.72.1.F8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aims-To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS). Methods-The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy fire preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of greater than or equal to 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of greater than or equal to 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose. Results-There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p<0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance. Conclusion-The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours aft er start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and nonpulmonary complications.
引用
收藏
页码:F8 / F13
页数:6
相关论文
共 50 条
  • [41] Transforming neonatal nursing: a randomized controlled trial comparing kangaroo care and standard protocols for survival in preterm infants with respiratory distress syndrome
    Osama Mohamed Elsayed Ramadan
    Afrah Madyan Alshammari
    Abeer Nuwayfi Alruwaili
    Nadia Bassuoni Elsharkawy
    Ali Alhaiti
    Nagwa Ibrahim Mabrouk Baraka
    BMC Nursing, 24 (1)
  • [42] A Randomized, Single-blind, Comparison Trial of Beractant Beraksurf™) versus Poractant Alfa (Curosurf®) in the Treatment of Respiratory Distress Syndrome in Preterm Infants
    Gharehbaghi, Manizheh Mostafa
    Sarbakhsh, Parvin
    Hosseini, Mohammadbagher
    Gharibzadeh, Safoora
    Shaseb, Elnaz
    PHARMACEUTICAL SCIENCES, 2023, 29 (01) : 52 - 58
  • [43] Comparison of adaptive support ventilation and synchronized intermittent mandatory ventilation in patients with acute respiratory distress syndrome: A randomized clinical trial
    Alikiaii, Babak
    Abbasi, Saeed
    Yari, Hamideh
    Akbari, Mojtaba
    Kashefi, Parviz
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2022, 27 (01): : 6
  • [44] The clinical effects of two non-invasive ventilation modes on premature infants with respiratory distress syndrome: A randomized controlled trial
    Wang, Hui
    Chen, Wenxiang
    Zhang, Yinlong
    MEDICINE, 2023, 102 (09) : E33142
  • [45] Nasal High-Frequency Oscillatory Ventilation in Preterm Infants with Moderate Respiratory Distress Syndrome: A Multicenter Randomized Clinical Trial
    Zhu, Xingwang
    Feng, Zhichun
    Liu, Chengjun
    Shi, Liping
    Shi, Yuan
    Ramanathan, Rangasamy
    NEONATOLOGY, 2021, : 325 - 331
  • [46] Thin-catheter Surfactant Application for Respiratory Distress Syndrome in Spontaneously Breathing Preterm Infants: A Meta-analysis of Randomized Clinical Trials
    Kesler, Hanan
    Lohmeier, Klaus
    Hoehn, Thomas
    Kribs, Angela
    Peinemann, Frank
    CURRENT PEDIATRIC REVIEWS, 2022, 18 (04) : 286 - 300
  • [47] Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants
    Proquitte, Hans
    Dushe, Thekla
    Hammer, Hannes
    Ruediger, Mario
    Schmalisch, Gerd
    Wauer, Roland R.
    RESPIRATORY MEDICINE, 2007, 101 (01) : 169 - 176
  • [48] A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
    Khan, Akram
    Benthin, Cody
    Zeno, Brian
    Albertson, Timothy E.
    Boyd, John
    Christie, Jason D.
    Hall, Richard
    Poirier, Germain
    Ronco, Juan J.
    Tidswell, Mark
    Hardes, Kelly
    Powley, William M.
    Wright, Tracey J.
    Siederer, Sarah K.
    Fairman, David A.
    Lipson, David A.
    Bayliffe, Andrew I.
    Lazaar, Aili L.
    CRITICAL CARE, 2017, 21
  • [49] Early Routine versus Late Selective Surfactant in Preterm Neonates with Respiratory Distress Syndrome on Nasal Continuous Positive Airway Pressure: A Randomized Controlled Trial
    Kandraju, Hemasree
    Murki, Srinivas
    Subramanian, Sreeram
    Gaddam, Pramod
    Deorari, Ashok
    Kumar, Praveen
    NEONATOLOGY, 2013, 103 (02) : 148 - 154
  • [50] A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
    Akram Khan
    Cody Benthin
    Brian Zeno
    Timothy E. Albertson
    John Boyd
    Jason D. Christie
    Richard Hall
    Germain Poirier
    Juan J. Ronco
    Mark Tidswell
    Kelly Hardes
    William M. Powley
    Tracey J. Wright
    Sarah K. Siederer
    David A. Fairman
    David A. Lipson
    Andrew I. Bayliffe
    Aili L. Lazaar
    Critical Care, 21